Respiratorius AB (publ) is a Swedish biotechnology and pharmaceutical company specializing in the development of drug candidates targeting serious respiratory and oncological conditions. Its portfolio includes therapeutic projects for aggressive lymphoma, specifically Diffuse Large B-Cell Lymphoma (DLBCL), and respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company focuses on candidate drugs like the VAL-001 oncology project and bronchodilators under the RESP-1000 and RESP-2000 series aimed at improving small airway function. Additionally, Respiratorius is developing a cardiovascular biomarker intended for positron-emission tomography (PET) imaging applications. With a research-driven approach, it serves primary markets including the United States and South Africa, positioning itself within the pharmaceuticals, biotechnology, and medical research sectors. The company benefits from leadership with extensive expertise in business development, clinical trials, and scientific research, underscoring its role as an innovator in therapeutic drug development for critical diseases.